NCT01954355View on ClinicalTrials.gov

LDE225 and Paclitaxel in Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

October 31, 2015

Study Completion Date

November 30, 2016

Conditions
Solid TumorOvarian Cancer
Interventions
DRUG

LDE225

400, 600 and 800 mg OD

DRUG

Paclitaxel

80 mg/m2 (days 1, 8, 15)

Trial Locations (4)

1011

Centre Pluridisciplinaire d'Oncologie CHUV, Lausanne

6500

Istituto Oncologico della Svizzera Italiana, Bellinzona

7000

Kantonsspital Graubünden, Chur

9007

Kantonsspital St. Gallen, Sankt Gallen

All Listed Sponsors
lead

Swiss Cancer Institute

OTHER

NCT01954355 - LDE225 and Paclitaxel in Solid Tumors | Biotech Hunter | Biotech Hunter